Kairos Pharma (NYSEAMERICAN:KAPA) Coverage Initiated at HC Wainwright

HC Wainwright assumed coverage on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $12.00 price target on the stock.

KAPA has been the topic of a number of other research reports. Maxim Group started coverage on Kairos Pharma in a research note on Thursday, March 27th. They issued a “buy” rating and a $4.00 target price on the stock. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Kairos Pharma in a research note on Monday, March 31st.

Kairos Pharma Price Performance

Shares of NYSEAMERICAN:KAPA opened at $1.06 on Thursday. Kairos Pharma has a 12-month low of $0.85 and a 12-month high of $4.00. The firm’s fifty day moving average is $1.23.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.